Trial intelligence / Profile preview

Photodynamic therapy with topical Metvix for actinic keratosis in organ transplant recipients

2012-002233-11Phase 4Completed

Sponsor
Bispebjerg and Frederiksberg Hospital
Start
Jun 2012
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4 trial of methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Lesion response rate in the treatment area in each patient. Started Jun 2012; status: completed.

02

Drugs

methyl aminolevulinate
03

Conditions

actinic keratosis (AK)

Beyond the preview

Go deeper on 2012-002233-11.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-002233-11.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call